You are here
P&T April 2017
As legislation is drafted to replace Obamacare, pharmaceutical issues—including controlling drug prices, expanding or contracting drug access, and incentivizing the development of generic drugs—are expected to be at the forefront of debate.
The authors explore efficacy and safety outcomes in multiple degrees of renal impairment when using FDA-approved dosing regimens for enoxaparin and find that a more multitiered dosing strategy appears to be needed.
Using a retrospective chart review, the authors compare the effectiveness of these two methods of administration in intensive care unit patients with septic shock.
While an educational video led to improvements in short-term knowledge, patients did not retain their understanding at one month, suggesting that future studies should evaluate other strategies to improve long-term retention of knowledge.
We present immunotherapies, biosimilars, and molecular-targeted agents in late-stage development for patients with advanced colorectal cancer.
One clinician’s controversial position against routine use of opioids for chronic pain.
We focus on liver-directed cancer therapy and the role of yittrium-90, as well as one clinician’s controversial position against routine use of opioids for chronic pain.
Twelve persistent safety gaffes that need resolution
FDA pleases no one with final guidance on biological and biosimilar naming
Approvals, new indications, regulatory activities, and more
Abuse-deterrent hydrocodone bitartrate (Vantrela ER) for long-term opioid treatment; etelcalcetide (Parsabiv) for secondary hyperparathyroidism in patients with chronic kidney disease on hemodialysis; and deflazacort (Emflaza) for Duchenne muscular dystrophy
Flibanserin (Addyi) for female sexual interest/arousal disorder in premenopausal women